lacosamide + levetiracetam

Lacosamide + levetiracetam is a combination therapy consisting of two antiepileptic drugs used primarily for the treatment and prevention of epilepsy, particularly in patients with refractory partial (focal) seizures. Lacosamide is a functionalized amino acid that enhances the slow inactivation of voltage-gated sodium channels and modulates collapsin response mediator protein 2 (CRMP-2), thereby stabilizing hyperexcitable neuronal membranes and reducing abnormal neuronal connections[6][8][10]. Levetiracetam acts by binding to synaptic vesicle protein 2A (SV2A), which modulates neurotransmitter release and stabilizes electrical activity in the brain[9]. The combination has demonstrated synergistic effects, leading to improved seizure control compared to monotherapy, with studies showing enhanced therapeutic efficacy, improved neural function, higher response rates, reduced seizure frequency, and increased quality of life for patients with refractory epilepsy[1][5][7]. Fixed-dose combinations are available as oral tablets or parenteral formulations for coordinated or simultaneous release of both drugs[4].